Literature DB >> 2374209

A combined therapy of hyperthermia and tumor necrosis factor for nude mice bearing KK-47 bladder cancer.

T Amano1, K Kumini, K Nakashima, T Uchibayashi, H Hisazumi.   

Abstract

A combined therapy of hyperthermia (43.5 C) and tumor necrosis factor (10(3) and 10(4) units) for the treatment of experimental bladder carcinoma KK-47 in athymic mice was studied. Briefly, mice were injected subcutaneously with 10(7) disaggregated cells. When the tumors were 250 mm3 in size, tumor necrosis factor was administered, either intravenously or by intratumor injection. Intravenous injection was 10(3) to 10(4) units tumor necrosis factor in the tail vein and intratumor was 10(3) to 10(4) units injected directly into the center of the tumor. Immediately following injection, the tumor bearing leg was placed in a 43.5 C water bath for 20 minutes. Tumor size was monitored once a week for seven weeks and the animals were divided into control, hyperthermia alone, tumor necrosis factor alone and combined therapy. Results of the study showed no significant difference in 10(3) units of tumor necrosis factor intravenously versus control but a significant regression in hyperthermia alone. Anti-tumor effects significantly increased in hyperthermia plus 10(3) units tumor necrosis factor versus hyperthermia alone. Similar results were seen with 10(4) units tumor necrosis factor intravenously though in the combination group of hyperthermia and tumor necrosis factor, eight mice of eight died one to three days following treatment. In those receiving intratumor injections, there was no difference between tumor necrosis factor or control. Tumor necrosis factor with hyperthermia had the approximate same characteristics as hyperthermia alone and therefore there was no synergistic finding. These results reflect on the suggestion that the combination therapy of hyperthermia and systemic administration of the proper dosage of tumor necrosis factor may produce synergistic anti-cancer effects in bladder cancer patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2374209     DOI: 10.1016/s0022-5347(17)39463-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Ultraweak biophoton emission imaging of transplanted bladder cancer.

Authors:  T Amano; M Kobayashi; B Devaraj; M Usa; H Inaba
Journal:  Urol Res       Date:  1995

Review 2.  Biophoton detection and low-intensity light therapy: a potential clinical partnership.

Authors:  Joseph Tafur; Eduard P A Van Wijk; Roeland Van Wijk; Paul J Mills
Journal:  Photomed Laser Surg       Date:  2010-02       Impact factor: 2.796

3.  Cytokine-mediated antitumor effect of bacillus Calmette-Guérin on tumor cells in vitro.

Authors:  H Kurisu; H Matsuyama; Y Ohmoto; T Shimabukuro; K Naito
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

4.  A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer.

Authors:  J W Van Hattum; E M Scutigliani; R F C P A Helderman; R Zweije; H M Rodermond; A L Oei; J Crezee; J R Oddens; T M De Reijke; P M Krawczyk
Journal:  Sci Rep       Date:  2022-04-29       Impact factor: 4.996

5.  Thermal enhancement of both tumour necrosis factor alpha-induced systemic toxicity and tumour cure in rats.

Authors:  J van der Zee; G J van den Aardweg; G C van Rhoon; A P van den Berg; R de Wit
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

Review 6.  Ultraweak photon emission as a non-invasive health assessment: a systematic review.

Authors:  John A Ives; Eduard P A van Wijk; Namuun Bat; Cindy Crawford; Avi Walter; Wayne B Jonas; Roeland van Wijk; Jan van der Greef
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

7.  Enhancement of blood stasis and vascular permeability in Meth-A tumors by administration of hyperthermia in combination with tumor necrosis factor.

Authors:  H Umeno; N Watanabe; N Yamauchi; N Tsuji; T Okamoto; Y Niitsu
Journal:  Jpn J Cancer Res       Date:  1994-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.